ARTICLE | Top Story
Non-approvable letter for Curis' OP-1
January 30, 2001 8:00 AM UTC
CRIS said that partner Stryker (Kalamazoo, Mich.) received a non-approvable letter from the FDA for Osteogenic protein-1 to treat nonunion fractures of the tibia. OP-1 was developed by CRIS and is lic...